The Severity of COVID-19 in Patients with Nonalcoholic Fatty Liver Disease in Korea
10.4332/KJHPA.2021.31.4.472
- Author:
Hyeki PARK
1
;
Hyun JOE
Author Information
1. HIRA Research Institute, Health Insurance Review & Assessment Service, Wonju, Korea
- Publication Type:ORIGINAL ARTICLE
- From:Health Policy and Management
2021;31(4):472-478
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Early identification of patients who are highly likely to develop severe illness among confirmed cases of coronavirus disease 19 (COVID-19) can be expected to lead to effective treatment. This study therefore aimed to determine whether the presence of nonalcoholic fatty liver disease (NAFLD) has an impact on the exacerbation of COVID-19 symptoms.
Methods:The study used the Korean National Health Insurance claim data for treatment of COVID-19 patients in 2020. NAFLD includes nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). The outcome variables used were hospitalization and the use of medical devices. Hospitalization was defined by a length of stay exceeding one day and the use of medical devices was defined as one or more uses of a ventilator or extracorporeal membrane oxygenation. Multivariable logistic regression analysis was performed to determine if there was a difference in the hospitalization and use of medical devices of COVID-19 patients depending on the presence of NAFLD.
Results:The odds ratio of hospitalization was 1.059, indicating slightly higher odds of hospitalization for patients with NAFL or NASH compared to those without the conditions, but it was not statistically significant (0.969–1.156). On the other hand, the odds ratio of use of medical devices was high at 1.667 and was statistically significant (1.111–2.501).
Conclusion:The study results found NAFLD to be a risk factor that can exacerbate symptoms in COVID-19 patients. Accordingly, it is necessary to identify NAFLD patients through preemptive screening and provide them with appropriate treatments.
